Warning labels for certain steroid-based allergy and asthma drugs provide sufficient warnings about potential side effects -- including stunted growth -- in children and teenagers, a U.S. panel of medical experts concluded on Wednesday. The Food and Drug Administration advisory panel reviewed safety information related to several allergy and asthma drugs, including GlaxoSmithKline Plc’s Advair, Flonase and Flovent and AstraZeneca Plc’s Pulmicort/Rhinocort.
